Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response

Shi,Huaiping; Li,Wenye

doi:10.3892/ol.2013.1776

Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response

Authors:
- Huaiping Shi
- Wenye Li
View Affiliations

Affiliations: College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi 712100, P.R. China
Published online on: December 27, 2013 https://doi.org/10.3892/ol.2013.1776
Pages: 820-826

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human lactoferrin (hLF) is a multifunctional glycoprotein that inhibits cancer growth. However, the inhibitory effect of this glycoprotein in cervical cancer remains inconclusive. This study investigated the efficacy of hLF on the inhibition of U14 cervical cancer in vivo. Recombinant adenovirus carrying hLF (Ad‑hLF) were constructed. Mice inoculated with U14 cells were randomly allocated to four treatments: i) Phosphate‑buffered saline (negative control), ii) Ad‑green fluorescent protein (negative control), iii) Ad‑hLF (studied) or iv) cyclophosphamide (CTX; positive control). Tumor growth, as well as levels of natural killer (NK) cells, CD4+ and CD8+ peripheral blood T lymphocyte subpopulations, serum cytokines and vascular endothelial growth factor (VEGF) in tumor tissues were detected. Compared with the negative controls, tumor growth was inhibited by hLF and mice lifespans in the Ad‑hLF‑treated group were prolonged to reach the levels of the CTX‑treated group. The activity of tumor‑killing NK cells was upregulated by hLF. Moreover, the number of CD4+ and CD8+ peripheral blood T lymphocyte subpopulations increased following treatment with Ad‑hLF. Treatment with Ad‑hLF increased the levels of serum interferon‑γ, serum interleukin‑2 (IL‑2) and tumor necrosis factor‑α, and decreased the levels of serum IL‑4 in tumor‑bearing mice. The expression of VEGF in tumor tissues was downregulated by hLF. In conclusion, hLF inhibits the growth of U14 solid tumors by modulating the immune response of tumor‑bearing mice.

View Figures

View References

1	Metz-Boutigue MH, Jollès J, Mazurier J, Schoentgen F, Legrand D, Spik G, et al: Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem. 145:659–676. 1984. View Article : Google Scholar : PubMed/NCBI
2	Kanyshkova TG, Buneva VN and Nevinsky GA: Lactoferrin and its biological functions. Biochemistry (Mosc). 66:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
3	Nuijens JH, van Berkel PH and Schanbacher FL: Structure and biological actions of lactoferrin. J Mammary Gland Biol Neoplasia. 1:285–295. 1996. View Article : Google Scholar : PubMed/NCBI
4	Levay PF and Viljoen M: Lactoferrin: a general review. Haematologica. 80:252–267. 1995.PubMed/NCBI
5	Vorland LH: Lactoferrin: a multifunctional glycoprotein. APMIS. 107:971–981. 1999. View Article : Google Scholar : PubMed/NCBI
6	Liu T, Zhang YZ and Wu XF: High level expression of functionally active human lactoferrin in silkworm larvae. J Biotechnol. 118:246–256. 2005. View Article : Google Scholar : PubMed/NCBI
7	van der Strate BW, Beljaars L, Molema G, Harmsen MC and Meijer DK: Antiviral activities of lactoferrin. Antiviral Res. 52:225–239. 2001.
8	Cumberbatch M, Dearman RJ, Uribe-Luna S, Headon DR, Ward PP, Conneely OM and Kimber I: Regulation of epidermal Langerhans cell migration by lactoferrin. Immunology. 100:21–28. 2000. View Article : Google Scholar : PubMed/NCBI
9	Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K and Azuma I: Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res. 88:184–190. 1997. View Article : Google Scholar : PubMed/NCBI
10	Cho E, Smith-Warner SA, Spiegelman D, Beeson WL, van den Brandt PA, Colditz GA, et al: Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst. 96:1015–1022. 2004. View Article : Google Scholar : PubMed/NCBI
11	Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, Takasuka N, et al: Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol. 443:273–284. 1998. View Article : Google Scholar
12	He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998. View Article : Google Scholar : PubMed/NCBI
13	Rees S, Coote J, Stables J, Goodson S, Harris S and Lee MG: Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques. 20:102–104. 106108–110. 1996.
14	Cheng M, Zhang J, Jiang W, Chen Y and Tian Z: Natural killer cell lines in tumor immunotherapy. Front Med. 6:56–66. 2012. View Article : Google Scholar : PubMed/NCBI
15	Kiessling R, Klein E and Wigzell H: ‘Natural’ killer cells in the mouse. I Cytotoxic cells with specificity for mouse Moloney leukemia cells Specificity and distribution according to genotype. Eur J Immunol. 5:112–117. 1975.
16	Glässner A, Eisenhardt M, Krämer B, Körner C, Coenen M, Sauerbruch T, et al: NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest. 92:967–977. 2012.
17	Kuss I, Hathaway B, Ferris RL, Gooding W and Whiteside TL: Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 10:3755–3762. 2004. View Article : Google Scholar
18	Tembhre MK and Sharma VK: T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol. 169:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tie J and Desai J: Antiangiogenic therapies targeting the vascular endothelial growth factor signaling system. Crit Rev Oncog. 17:51–67. 2012. View Article : Google Scholar : PubMed/NCBI
20	Masuda C, Wanibuchi H, Sekine K, Yano Y, Otani S, Kishimoto T, et al: Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. Jpn J Cancer Res. 91:582–588. 2000. View Article : Google Scholar
21	Bezault J, Bhimani R, Wiprovnick J and Furmanski P: Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 54:2310–2012. 1994.PubMed/NCBI
22	Iigo M, Kuhara T, Ushida Y, Sekine K, Moore MA and Tsuda H: Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin Exp Metastasis. 17:35–40. 1999. View Article : Google Scholar : PubMed/NCBI
23	Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M and Tsuda H: Inhibitory effects of bovine lactoferrin on intestinal polyposis in the Apc(Min) mouse. Cancer Lett. 134:141–145. 1998. View Article : Google Scholar : PubMed/NCBI
24	Ushida Y, Sekine K, Kuhara T, Takasuka N, Iigo M, Maeda M and Tsuda H: Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn J Cancer Res. 90:262–267. 1999. View Article : Google Scholar : PubMed/NCBI
25	Tanaka T, Kawabata K, Kohno H, Honjo S, Murakami M, Ota T and Tsuda H: Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn J Cancer Res. 91:25–33. 2000. View Article : Google Scholar : PubMed/NCBI
26	Li WY, Li QW, Han ZS, Jiang ZL, Yang H, Li J and Zhang XB: Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 26:477–483. 2011. View Article : Google Scholar : PubMed/NCBI
27	Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, et al: Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther. 7:599–615. 2007. View Article : Google Scholar : PubMed/NCBI
28	Trapani JA and Smyth MJ: Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2:735–747. 2002. View Article : Google Scholar : PubMed/NCBI
29	Kannan Y, Yu J, Raices RM, Seshadri S, Wei M, Caligiuri MA and Wewers MD: IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells. Blood. 117:2855–2863. 2011.
30	Raja A: Immunology of tuberculosis. Indian J Med Res. 120:213–232. 2004.
31	Van Elssen CH, Vanderlocht J, Oth T, Senden-Gijsbers BL, Germeraad WT and Bos GM: Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood. 118:2473–2482. 2011.
32	Reefman E, Kay JG, Wood SM, Offenhäuser C, Brown DL, Roy S, et al: Cytokine secretion is distinct from secretion of cytotoxic granules in NK cells. J Immunol. 184:4852–4862. 2010. View Article : Google Scholar : PubMed/NCBI
33	Smyth MJ, Hayakawa Y, Takeda K and Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2:850–861. 2002. View Article : Google Scholar : PubMed/NCBI
34	Shanker A, Buferne M and Schmitt-Verhulst AM: Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology. 129:41–54. 2010. View Article : Google Scholar : PubMed/NCBI
35	Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP and van den Brink MR: Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One. 7:e352222012. View Article : Google Scholar
36	Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature. 392:245–252. 1998. View Article : Google Scholar : PubMed/NCBI
37	Blanchard DK, Wei S, Duan C, Pericle F, Diaz JI and Djeu JY: Role of extracellular adenosine triphosphate in the cytotoxic T-lymphocyte-mediated lysis of antigen presenting cells. Blood. 85:3173–3182. 1995.PubMed/NCBI
38	Hamza T, Barnett JB and Li B: Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 11:789–806. 2010. View Article : Google Scholar : PubMed/NCBI
39	Seger J, Zorzella-Pezavento SF, Pelizon AC, Martins DR, Domingues A and Sartori A: Decreased production of TNF-alpha by lymph node cells indicates experimental autoimmune encephalomyelitis remission in Lewis rats. Mem Inst Oswaldo Cruz. 105:263–268. 2010. View Article : Google Scholar
40	Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M and Angel P: Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J. 21:6321–6329. 2002. View Article : Google Scholar : PubMed/NCBI
41	Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, et al: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 167:3114–3122. 2001. View Article : Google Scholar
42	Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, et al: Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem. 284:4658–4666. 2009. View Article : Google Scholar : PubMed/NCBI
43	Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kämpgen E, et al: High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 184:741–746. 1996.PubMed/NCBI
44	Flesch IE, Hess JH, Oswald IP and Kaufmann SH: Growth inhibition of Mycobacterium bovis by IFN-gamma stimulated macrophages: regulation by endogenous tumor necrosis factor-alpha and by IL-10. Int Immunol. 6:693–700. 1994.
45	Alcami A and Koszinowski UH: Viral mechanisms of immune evasion. Mol Med Today. 6:365–372. 2000. View Article : Google Scholar
46	Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K and Saiki I: IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood. 100:1728–1733. 2002.PubMed/NCBI
47	Davis-Smyth T, Chen H, Park J, Presta LG and Ferrara N: The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15:4919–4927. 1996.
48	Carmeliet P: Angiogenesis in health and disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
49	Sukhramani PS and Suthar MP: VEGF inhibitors for cancer therapy. IJPSDR. 2:1–11. 2010.